NCT00456378终止不适用
A Prospective, Randomized, Controlled Pivotal Clinical Investigation of DIAM™ Spinal Stabilization System in Patients With Lumbar Degenerative Disc Disease.
Medtronic Spinal and Biologics53 个研究点 分布在 1 个国家目标入组 311 人开始时间: 2006年12月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 311
- 试验地点
- 53
- 主要终点
- Overall Success
研究概览
简要总结
The purpose of this study is to establish the safety and effectiveness of the DIAM™ Spinal Stabilization System in the treatment of moderate single-level lumbar degenerative disc disease.
详细描述
This pivotal clinical trial is being conducted to evaluate the DIAM™ Spinal Stabilization System for the treatment of single-level moderate lumbar degenerative disc disease. The implant under investigation in this clinical trial is the DIAM Spinal Stabilization System, and the device will be implanted using a posterior surgical approach. Patients in the control group will receive nonoperative treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Each patient participating in this clinical trial must meet all of the following inclusion criteria:
- •Has moderate low back pain secondary to lumbar degenerative disc disease at a single level from L2 - L
- •Low back pain is defined as persistent back pain, with or without radicular pain, with current episode of less than one year duration. Degenerative disc disease is confirmed by patient history, physical examination, and radiographic studies with one or more of the following factors (as measured radiographically by MRI scans or x-rays):
- •Decreased disc height >2mm, compared to the disc space at the next adjacent (superior or inferior, whichever has greater disc height) spinal level;
- •Scarring/thickening of the ligamentum flavum, annulus fibrosis, or facet joint capsule;
- •Herniated nucleus pulposus.
- •Is 18-70 years of age, inclusive, and is skeletally mature.
- •Has pre-treatment Oswestry score ≥
- •Has pre-treatment back pain score of ≥ 8 based on the Pre-Treatment Back and Leg Pain Questionnaire (Back Pain Intensity + Back Pain Frequency).
- •Has been treated nonoperatively (e.g. bed rest, physical therapy, medications, TENS, manipulation, and/or spinal injections) for a period of at least 6 weeks and not more than 6 months prior to enrollment in the clinical study.
- •If of child-bearing potential, patient is not pregnant or nursing and agrees not to become pregnant during the study period.
- •Is willing and able to participate in either of the randomized treatments for the duration of the study follow-up period. If the patient is randomized to the investigational group, he/she is willing to undergo surgery and receive the DIAM device. If the patient is randomized to the control group, he/she is willing to undergo all four nonoperative treatments.
- •Is willing and able to comply with the study plan and able to understand and sign the Patient Informed Consent Form.
排除标准
- •A patient meeting any of the following criteria is to be excluded from this clinical trial:
- •Has disc height loss > 67% at the involved level, compared to the next adjacent (superior or inferior, whichever has greater disc height) spinal level
- •Has Arachnoiditis.
- •Has a primary diagnosis of a spinal disorder other than degenerative disc disease at the involved level.
- •Requires treatment of degenerative disc disease at more than one lumbar level.
- •Has had all of the following nonoperative treatments (prescribed medications, active physical therapy, spinal injections, and patient education) within the past 6 weeks.
- •Has a sequestered herniated nucleus pulposus.
- •Has had any previous surgery at the involved or adjacent spinal levels (including procedures such as rhizotomy).
- •Has received any intradiskal ablation therapy, such as IDET.
- •Has congenital or iatrogenic posterior element insufficiency (e.g. facet resection, spondylolysis, pars fracture, or Spinal Bifida Occulta).
- •Has back pain (with or without leg, buttock, or groin pain) that is not alleviated in any spinal position.
- •Has a motor deficit of the lower extremity.
- •Has cauda equina syndrome.
- •Has compression of nerve roots with neurogenic bowel (fecal incontinence) or bladder (urinary retention or incontinence) dysfunction.
- •Has been previously diagnosed with clinically significant peripheral neuropathy.
- •Has significant vascular disease causing vascular claudication.
- •Has a medical contraindication that prevents the patient from receiving spinal injections (i.e., allergy to contrast media used to aid in placement of the needle in the epidural space).
- •Has ventral spondylolisthesis with more than 2 mm of translation at the involved level.
- •Has evidence of prior fracture or trauma to the L1, L2, L3, L4, or L5 levels in either compression or burst.
- •Has lumbar scoliosis with a Cobb angle of greater than 15°.
- •Has lumbar kyphosis or flat back syndrome.
- •Has sustained a hip fracture within the last year.
- •Has any of the following (if "Yes" to any of the below risk factors, a lumbar spine DEXA Scan will be required to determine eligibility.):
- •Previous diagnosis of osteoporosis, osteopenia, or osteomalacia.
- •Postmenopausal Non-Black female over 60 years of age who weighs less than 140 pounds.
- •Postmenopausal female who has sustained a non-traumatic hip, spine or wrist fracture.
- •Male over the age of 60 who has sustained a non-traumatic hip or spine fracture.
- •If the level of DEXA T-score is -1.0 or lower (i.e., -1.5, -2.0, etc.), the patient is excluded from the study.
- •Has obesity defined by BMI greater than or equal to
- •(Refer to the BMI Table provided in the CIP.)
- •Has a documented allergy to silicone, polyethylene, titanium, or latex.
- •Has overt or active bacterial infection, either local or systemic, and/or potential for bacteremia.
- •Has a suppressed immune system or has taken steroids at any dose daily for more than one month within the last year (excluding low dose inhalers for the treatment of asthma).
- •Has a history of autoimmune disease.
- •Has presence of active malignancy or prior history of malignancy within the last 5 years (except for basal cell carcinoma of the skin).
- •Has presence or prior history of a spinal malignancy.
- •Has chronic or acute renal and/or hepatic failure or prior history of renal and/or hepatic parenchymal disease.
- •Has any disease (e.g., neuromuscular disease) that would preclude accurate clinical evaluation of the safety and effectiveness of the treatment regimens in this study.
- •Has received treatment with an investigational therapy (device and/or pharmaceutical) within 30 days prior to entering the study or such treatment is planned during the 24 months following enrollment in the study.
- •Has an implantable metal device (e.g., stimulator, pacemaker) and is unable to have an MRI.
- •Is an alcohol and/or drug abuser, as defined by currently undergoing treatment for alcohol and/or drug abuse.
- •Is mentally incompetent. If questionable, obtain psychiatric consult.
- •Has a Waddell Signs of Inorganic Behavior score of 3 or greater.
- •Is a prisoner.
研究组 & 干预措施
DIAM™ spinal stabilization system
Experimental
Implantation of the DIAM Spinal Stabilization System
干预措施: DIAM™ Spinal Stabilization System (Device)
Conservative care
Active Comparator
Conservative Care
干预措施: Conservative care (Procedure)
结局指标
主要结局
Overall Success
时间窗: 12 months
A patient will be considered an overall success if all of the following conditions are met: 1. Pain/disability (Oswestry) success; 2. No serious adverse event classified as "implant associated", "implant-/surgical procedure associated", or "nonoperative treatment associated"; and 3. For patients in the investigational group, no additional surgical procedure at the involved level classified as a failure. For patients in the control group, no "treatment surgery" at the involved level that was the result of a poor response to conservative care treatment.
次要结局
- Pain/Disability Status(12 months)
- Neurological Status(12 months)
- Pain Status (Back Pain and Leg Pain)(12 months)
- General Health Status(12 months)
研究者
研究点 (53)
Loading locations...
相似试验
终止
3 期
DIAM™ Spinal Stabilization System vs. Decompression, Formerly vs. Posterolateral FusionDegenerative Lumbar Spinal StenosisNCT00627497Medtronic Spinal and Biologics32
Unknown
不适用
DIAM™ Spinal Stabilization System Long Term Follow up Clinical PlanLow Back PainNCT05201573Companion Spine, LLC175
招募中
不适用
Safety and Effectiveness Evaluation of Spinal Laminectomy RobotLumbar Disc HerniationLumbar Spinal StenosisNCT06593574Peking University Third Hospital70
已完成
不适用
Anticipatory Muscle Control and Effect of Stabilizing Exercises in Patients With Subacute and Chronic Low Back PainLow Back PainNCT00201513Norwegian University of Science and Technology99
Unknown
不适用
Safety and Efficacy of Spinous Balloon Dilatation Catheter in CAD TreatmentCoronary Artery DiseaseNCT05342961CCRF Inc., Beijing, China160